Chapter 13: Muscarinic Agonists and Cholinesterase Inhibitors

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about pharmacology, there's this expectation of a single clean target.

Like a sniper, right?

You have a specific symptom, you give a specific pill and that symptom just, you know, goes away, it's binary.

Yeah, exactly.

It feels very contained.

You're aiming at one specific receptor and one specific organ and ideally everything else is just left alone.

Right.

But then you step into the world of the autonomic nervous system and suddenly that sniper rifle is just, it's gone.

We're looking at a pharmacologic landscape that is honestly more like a shotgun blast.

Really is.

I mean, it is the absolute definition of systemic impact.

Yeah.

Basically cannot touch one part of this system without sending ripples through the entire body.

Seriously.

So if you are an advanced practice nursing or physician assistant student listening right now, consider this deep dive your ultimate cheat code.

Definitely.

Our mission today is to take the core concepts from Chapter 13 of LANDS Pharmacotherapeutics, covering muscarinic agonists and cholinesterase inhibitors and translate all that dense pathophysiology into, well, practical clinical decision making.

Right.

And to give you the broad overview first, we're dealing with cholinergic drugs.

These are agents that basically influence cholinergic receptors by either mimicking or blocking the actions of acetylcholine.

Acetylcholine.

Right.

The main neurotransmitter here.

Exactly.

Now there are several categories of cholinergic drugs, but today we are focusing purely on two that enhance cholinergic action.

First, the muscarinic agonists, which work through direct action.

And second, the cholinesterase inhibitors, which work through indirect action.

Okay, let's unpack this because, I mean, before we can even think about handing a patient a pill, we have to understand the foundational blueprint.

If this system is a shotgun blast, like we said, how do we predict what we're going to hit?

Well, you predict it by understanding the targets themselves, the cholinergic receptors.

There are three major subtypes you need to track here.

Okay, lay them out for us.

First, the muscarinic receptors.

These are located in sweat glands, blood vessels, and all the organs regulated by the parasympathetic nervous system.

So all the internal organ stuff.

Yeah, exactly.

When you activate them, you trigger parasympathetic responses.

Yeah.

So a lower heart rate, increased gland secretion, and the contraction of smooth muscle.

Right.

The classic rest and digest or wet and slow response.

I've got it.

Then we have the second subtype, which is nicotinic N, with the N standing for neuronal.

These are located in all the ganglia of the autonomic nervous system, promoting ganglionic transmission.

And finally, the third subtype is nicotinic M, with the M standing for muscle.

These are found at the neuromuscular junctions, and their activation causes skeletal muscle contraction.

I actually often describe acetylcholine as a biological master key.

Oh, I love that visual.

So the body essentially uses one single key, but that key is capable of opening three entirely different locks, right?

The muscarinic lock for the organs, the nicotinic N lock for the ganglia, and the nicotinic M lock for the muscles.

So predicting what a drug will do, and especially predicting its adverse effects, is just a matter of knowing which of those specific locks it can open.

Precisely.

Let's apply that to the first set of keys, the direct -acting muscarinic agonists.

Because these drugs closely resemble the effects of stimulating parasympathetic nerves, they're also called parasympathomimetics.

The classic prototype drug here is bethanical.

Okay, bethanical.

How exactly does bethanical interact with those locks?

It binds reversibly to muscarinic receptors to cause activation.

And crucially, at therapeutic doses, it has little to no effect on the nicotinic receptors.

Oh, so it only opens the muscarinic locks.

Right.

Only the muscarinic ones.

But what does that actually look like for the patient?

Because if it hits muscarinic receptors all over the body, the effects must be, you know, pretty widespread.

Oh, they are.

You see bradycardia, sweating, salivation, bronchial constriction, and increased tone of motility in the GI tract.

Wait, hold on.

If it makes a patient sweat profusely, drops their heart rate, and causes GI cramping, why on earth would someone take this?

What is it actually prescribed for?

It sounds counterintuitive, I know.

But despite all those widespread actions, it's really approved for only one primary condition, which is non -obstructive urinary retention.

Urinary retention.

Yeah.

It works brilliantly for this because it relaxes the trigone and sphincter muscles while simultaneously contracting the detrusor muscle of the bladder wall.

Ah, so it essentially squeezes the bladder while opening the exit.

Exactly.

There's also an off -label use for GI paralysis, or ad dynamic alias, where that increased motility helps, you know, wake up the gut.

I see.

So it has this one very specific job, but it comes with all this systemic baggage.

And looking at the pharmacokinetics, I noticed a huge clinical pearl about how it's absorbed.

Oh, the charge.

Yeah.

Botanical is a quaternary ammonium compound, meaning it carries a positive charge.

Practically speaking, what does that charge do?

That positive charge makes the cross -cell membranes very poorly.

Only a tiny fraction of an oral dose actually gets absorbed into the bloodstream.

It usually peaks in about 1 to 1 .5 hours.

Which explains why oral doses need to be anywhere from like 10 to 50 milligrams multiple times a day.

Exactly.

Now let's talk contraindications, because the logic here is fascinating to me.

You obviously can't give botanical if there is a physical obstruction in the urinary or GI tract.

No, definitely not.

If there's a blockage and you give a drug that dramatically increases pressure and propulsive contractions, you could literally cause a rupture of the bladder or the bowel wall.

It's incredibly hazardous.

Wow.

Yeah, that makes sense.

It's also contraindicated in peptic ulcer disease because it increases gastric acid secretion, which could cause an ulcer to bleed or perforate.

But I want to circle back to the heart rate.

Botanical slows the heart down, but the text strictly contraindicates it for patients with

hyperthyroidism because it might cause dysrhythmias like a racing irregular heartbeat that feels completely backward.

If the drug slows the heart, why does it cause a racing heart in these specific patients?

It's a great question.

What's fascinating here is how the body actually attempts to compensate for the drug.

When you give botanical, it causes vasodilation, which drops the blood pressure.

In response to that sudden hypotension, the bowel receptor reflex kicks in.

The nervous system basically panics.

It senses the drop in pressure and tells the sympathetic nerves to release norepinephrine to raise the blood pressure back up.

Oh, I get it.

So the body's natural survival reflex is actively fighting the drug.

Precisely.

Now, in a normal patient, that burst of norepinephrine just restores normal cardiac output.

But in a patient with hyperthyroidism,

their heart is exquisitely sensitive to norepinephrine.

So that sudden reflex release overstimulates the heart and triggers a dangerous dysrhythmia.

Wow.

So the drug doesn't directly cause the racing heart, the body's panicked reaction to the drug causes it.

That's it.

Exactly.

What about the asthma contraindication then?

Well, think about the biological logic of the rest and digest state.

When you are resting, your body doesn't need maximum oxygen airflow, right?

True.

The parasympathetic nervous system naturally constricts the bronchioles to conserve energy.

For a healthy person, that's fine.

But for an asthmatic, you are severely compromising an airway that is already prone to narrowing.

That makes perfect sense.

We can't just memorize drug facts.

We really have to trace the underlying physiology.

So are all these direct agonists just used for the bladder and gut?

No, actually.

There are others in this family that utilize the exact same direct mechanism, but we use them for entirely different therapeutic goals, specifically conditions of the head and neck.

For instance, C.

Vime Lyon.

Oh, right.

C.

Vime Lyon is indicated for xerostomia's severe dry mouth, specifically in patients with Sjogren's syndrome, which is an autoimmune disorder.

Yes.

It activates the muscarinic receptors on whatever residual healthy salivary gland tissue the patient has left, basically promoting salivation.

But because it's still a muscarinic agonist, it carries those same systemic adverse effects.

Like the sweating and stuff.

Right.

Excessive sweating, rhinitis, and importantly, meiosis.

Meiosis.

So constriction of the people.

By restricting the amount of light entering the eye, it blurs vision.

Right, exactly.

You absolutely have to warn your patients that driving at night can become highly dangerous.

For sure.

And then there's pilacarpine.

We usually see pilacarpine as topical drops for glaucoma, but oral pilacarpine under the brand name salagen is also used for dry mouth from Sjogren's syndrome or from like head and neck radiation damage.

Yep.

And this brings us to a massive clinical trap regarding drug interactions with these direct agonists.

Yes.

This is a huge prescribing hazard.

Many incredibly common medications like tricyclic antidepressants, first -generation antihistamines, certain antipsychotics, they have high anticholinergic activity, meaning they block muscarinic receptors.

It's a pharmacological tug of war.

If you prescribe C -Vimeline to help a patient produce saliva, but they are taking, say, over -the -counter diphenhydramine for their allergies.

The antihistamine basically acts like glue in the muscarinic lock.

Exactly.

The C -Vimeline can't get in.

The therapeutic effect is entirely canceled out.

The patient gets zero relief.

So we've talked about the controlled use of these drugs, but what happens if a patient gets too much?

Say they overdose or they're foraging and eat the wrong wild mushrooms.

That leads to muscarinic poisoning.

And the clinical picture is, well, it's severe.

The text uses two mnemonics, dumbbells and selige, to categorize the symptoms.

Yeah.

Instead of just rattling off the letters for SLDGE, let's look at what this actually does to a human being.

So we have salivation, lacrimation, urination, diaphoresis, GI cramping, emesis.

I mean, the patient is literally leaking from everywhere.

Pretty much.

Yeah.

They are sweating through their clothes, their eyes are tearing up, they are vomiting, and their smooth muscle is seizing.

It's a really intense physical crisis.

But if we connect this to the bigger picture, the real -life threats are actually found in the killer bees of that mnemonic.

The killer bees.

Right.

Okay, so their heart rate plummets, their airway spasms shut, and their lungs fill with massive amounts of secretions.

Exactly.

That combination is a fast track to cardiovascular and respiratory collapse.

Fortunately, the treatment is direct and highly specific.

You administer Atropine.

Yes.

Atropine is a selective muscarinic blocking agent.

It competes for the receptors, kicks out the agonist, and reverses the toxicity.

You push Atropine and immediately provide respiratory support.

Okay, so that covers the direct route, giving the body fake master keys.

Let's pivot to the indirect route.

We're looking at reversible cholinesterase inhibitors.

We are basically shifting from mimicking acetylcholine to preserving the acetylcholine the body is already making.

Right.

And for this, I want you to imagine acetylcholinesterase, the enzyme that breaks down acetylcholine, as a lightning -fast garbage disposal in the synapse.

A garbage disposal, okay.

Its entire biological purpose is to chew up acetylcholine the millisecond after it activates a receptor, keeping the area perfectly clean and ready for the next signal.

Here's where it gets really interesting.

A cholinesterase inhibitor is essentially taking a giant wrench and jamming it into the blades of that garbage disposal.

That is the perfect analogy.

The disposal is jammed.

The natural acetylcholine doesn't get cleared away, it just piles up in the synapse and it hits those receptors again and again and again.

The prototype drug for this indirect mechanism is pyridostigmine.

It's a reversible inhibitor.

It binds to the cholinesterase enzyme, effectively jamming it, but it splits away very slowly.

It keeps the enzyme busy for a while.

Now, does it only cause acetylcholine to pile up at muscarinic receptors?

No.

And that is a key difference between these indirect inhibitors and the direct agonists we just talked about.

Pyridostigmine does not care where the acetylcholine is piling up.

Oh, really?

Yeah, it lacks selectivity completely.

It causes enhanced transmission at all cholinergic junctions, muscarinic, ganglionic, and the neuromuscular junction.

What about its pharmacokinetics?

Does it share that positive charge we saw with bathanocol?

It does.

Pyridostigmine is also a positively charged compound.

Because of that charge, it cannot cross the blood -brain barrier.

So you get all these profound peripheral effects at the muscles and organs, but minimal effects on the central nervous system.

Exactly.

Which brings us to the exception that proves the rule, right?

Phisostigmine.

Yes, phisostigmine.

It's another reversible inhibitor, but it does not carry a charge.

And because it is uncharged, it readily slips across the blood -brain barrier.

That is a critical clinical difference.

Because it crosses into the brain, phisostigmine is the drug of choice to treat poisoning by atropine or antihistamines.

Oh, because it can get into the CNS.

Right.

It can reverse the central nervous system blockade that those drugs cause, which pyridostigmine simply cannot reach.

That makes total sense.

It's the exact same physiological logic used for certain Alzheimer's drugs, like Dumb Puzzle, Glantamine, and Rivastigmine.

They cross the blood -brain barrier and inhibit cholinesterase in the CNS, basically boosting acetylcholine levels in the brain to help with memory and cognition.

Spot on.

So those are the reversible inhibitors.

The wrench eventually falls out of the garbage disposal, but what if the wrench permanently welds itself to the blades?

The dark side of this pharmacology.

Irreversible inhibitors.

Yeah.

We were talking about the organophosphates.

These compounds contain a phosphorus atom that binds to cholinesterase so tightly that for all practical purposes, the bond is irreversible.

So the enzyme is just dead.

Permanently dead.

The body literally has to synthesize entirely new cholinesterase molecules to recover.

Furthermore, almost all of them are highly lipid soluble, meaning they absorb easily through all routes, including straight through the skin.

And their medical uses are incredibly narrow.

The text mentions only one, echothiophate, used topically for glaucoma, otherwise these chemicals are used as agricultural insecticides and, terrifyingly, as nerve agents like weapons of terrorism.

Yeah.

It's serious stuff.

When a patient is exposed to a toxic dose of an organophosphate, they enter a cholinergic crisis.

Because the enzyme is permanently disabled, acetylcholine floods every receptor in the body.

So everything goes into overdrive.

Exactly.

You see extreme muscarinic effects, basically the dumbbells and sole DGE picture on steroids.

You see severe CNS effects ranging from confusion to convulsions.

But the most lethal aspect happens at the nicotinic receptors of the neuromuscular junction.

Because if you constantly bombard a skeletal muscle with acetylcholine, it doesn't just stay flexed.

It eventually fatigues and gives up entirely.

Right.

It causes a depolarizing neuromuscular blockade.

You see initial muscle fasciculations, followed by profound weakness and, ultimately, complete paralysis.

And when that paralysis hits the diaphragm and the muscles of respiration.

Patient stops breathing.

Yeah.

It's fatal apnea.

The treatment protocol for this is intense and requires three immediate prongs.

First, you administer atropine to block the muscarinic receptors and stop the deadly bradycardia and airway secretions.

Yes.

Second, because atropine does nothing for paralyzed skeletal muscles, you must provide mechanical ventilation with oxygen.

Third, you give diazepam to suppress the CNS convulsions.

That's right.

And finally, you administer a specific antidote called pralidoxime.

But wait, you just said the organophosphate bond to the enzyme is truly irreversible.

So how does pralidoxime actually work?

Pralidoxime is unique.

It acts as a cholinesterase reactivator.

It chemically attacks the phosphorus bond and forces it to break, detaching the organophosphate from the enzyme.

But the catch is time.

It must be given quickly after exposure before the chemical bond ages and becomes permanently locked.

Also, pralidoxime carries a positive charge.

Meaning, it cannot cross the blood -brain barrier.

It can rescue the diaphragm, but it cannot reverse the central nervous system toxicity.

Exactly.

Now let's step into the clinic and apply cholinesterase inhibitors to their major therapeutic use, myasthenia gravis.

Let's break down the pathophysiology of MG first so we know what we're treating.

Myasthenia gravis is an autoimmune disorder.

The patient's own immune system produces antibodies that attack and destroy 70 to 90 percent of the nicotinic M receptors on their skeletal muscles.

So the nerves are firing perfectly fine.

The acetylcholine is releasing normally, but there are hardly any receptors left to catch the signal.

They have the keys, but their body has basically destroyed the locks.

Which results in fluctuating muscle weakness, a rapid predisposition to fatigue, supposis, which is drooping of the eyelids and severe dysphagia, or difficulty swallowing.

And to treat this, we use reversible cholinesterase inhibitors, primarily pyridostigmine.

By jamming that garbage disposal we talked about, we force whatever acetylcholine the patient does have to pile up in the synapse.

Exactly.

The sheer volume of acetylcholine helps overcome the massive deficit of receptors, increasing their muscle strength.

But dosing this requires immense clinical vigilance.

Because these patients suffer from dysphagia, you have to physically assess their ability to swallow before you hand them an oral dose of pyridostigmine.

That is a crucial nursing action.

If they can't swallow a simple sip of water, they will choke on the pill.

You have to immediately switch to parenteral medication.

It sounds like a constant tightrope walk.

Dosages are highly individualized.

You start small and titrate up.

Patients and families have to keep meticulous daily logs, right?

Oh, absolutely.

Times of drug administration, exactly when their fatigue sets in, their muscle strength before and after the dose, and any signs of excessive muscarinic stimulation.

And that tightrope walk leads to the ultimate clinical trap we need to cover, distinguishing between a myasthenic crisis and a cholinergic crisis.

This is vital.

A myasthenic crisis happens when the patient is under -medicated.

They don't have enough acetylcholine in the synapse, so they experience extreme muscle weakness and paralysis.

Left untreated, they stop breathing.

And you treat this by giving more cholinesterase inhibitor, like neostigmine.

Right.

But a cholinergic crisis happens when the patient is over -medicated.

They have way too much acetylcholine, causing that depolarizing neuromuscular blockade we just discussed with organophosphates.

The muscles are overstimulated to the point of paralysis.

And you treat this by withholding the inhibitor and giving atropine and respiratory support.

Both crises present with the exact same terrifying primary symptom, profound muscle weakness, and respiratory paralysis.

This raises an important question.

If a patient with M .G.

is wheeled into the ER, completely paralyzed and unable to breathe, how do you tell them apart?

Giving the wrong treatment could be fatal.

You look for the muscarinic signs, the S -L -W -D -E.

If the patient is paralyzed, but they are also drooling profusely, sweating through their clothes, and bradycardic, that is, a cholinergic crisis from an overdose.

Sign on.

If those wet, muscarinic signs are absent, it's a myasthenic crisis from underdosing.

It's a brilliant differential diagnosis based entirely on understanding receptor pharmacology.

Finally, this pharmacology dictates patient education.

Patients with M .G.

need to learn to adjust their own doses based on exertion.

Like timing their medication 30 to 60 minutes before a tiring activity, like eating a meal?

Yes.

They must never take an extra dose if they miss one because of the immediate risk of a cholinergic crisis.

And they must always wear a medical or bracelet so emergency personnel know exactly what they're dealing with if the patient loses the ability to communicate.

So what does this all mean?

It means you're ready to step into the clinic with confidence.

We've covered a profound amount of pharmacology today, but I want to leave you with a final thought to mull over.

Consider the sheer elegance and the terrifying fragility of the autonomic nervous system.

A single simple molecule like acetylcholine dictates everything from the blink of an eyelid to the rhythm of the heart.

Our pharmacologic interventions throwing these wrenches into the gears require a deep respect for that delicate biological balance.

Absolutely.

A huge thank you from the Last Minute Lecture team.

Go out there, trust your foundational knowledge, think through the physiology, and apply this safely in your advanced practice.

We'll see you on the next Deep Dive.